BDX
+0.0 · +0.00%
USD · NYSE

Becton Dickinson and Company(BDX) Stock Analysis | Healthcare

USD --+0.00%
Reward48Moderate
Risk28Low
75%Data
Thin 4% profit margin · 2.2% dividend yield
Defensive Anchor
Market Cap:52.30Bn
ⓘ
Reward Rating
48
Moderate
Reward Assessment
75% data coverage
Bottom 25% of stocksView factors
ⓘ
Risk Rating
28
Low
Risk Assessment
1 metric flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on BDX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for BDX, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $194.42.

What is Becton Dickinson and Company?

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.

BDX · Verdict

Moderate reward · low risk

BDX stands out on volatility and cash flow, but watch the balance sheet signal.

Based on 88% data coverage

BDX · Verdict

What’s working & what to watch

Strengths 2

  • Volatility95/100

    Top decile vs peers

  • Cash flow74/100

    12% free-cash-flow margin

Watchouts 2

  • Balance sheet34/100

    Interest covered 4.1×

  • Growth44/100

    Rev +5.0% CAGR · earnings -1.9%

Model-based scoring. For information only — not financial advice.

What is Becton Dickinson and Company?

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 52.30B, and a P/E ratio of 33.2x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (48)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Medical Instruments & Supplies names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryMedical Instruments & Supplies
Market Cap52.30B
P/E Ratio33.218
Dividend Yield2.23%
Beta0.258
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
73,491 shares
$689k
0
9-12months
41,249 shares
$231k
0